Survodutide

Survodutide, previously known as BI 456906, is a long-acting peptide designed to activate both the glucagon-like peptide-1 receptor and the glucagon receptor. This combination is scientifically interesting because the two receptors influence different but complementary aspects of metabolism. GLP-1 receptor activation is associated with reduced appetite, delayed gastric emptying, and improved glucose-dependent insulin signaling, while glucagon receptor activity influences hepatic energy metabolism and may contribute to increased energy expenditure.

The molecule was deliberately designed with greater relative activity at the GLP-1 receptor than at the glucagon receptor. The aim is to preserve the appetite and glycemic effects associated with GLP-1 signaling while adding glucagon-mediated effects on liver metabolism and energy balance. This distinguishes Survodutide from single GLP-1 agonists and from dual GIP/GLP-1 compounds such as Tirzepatide.

In a Phase 2 obesity trial, Survodutide produced clinically meaningful body-weight reductions across multiple dose groups compared with placebo. Separate Phase 2 research in biopsy-confirmed MASH also showed significant improvements in MASH without worsening of fibrosis, along with substantial reductions in liver fat. These findings have led to larger Phase 3 programs in both obesity and liver disease.